Diagnostic Imaging's Weekly Scan: October 8-October 14

New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.

In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

In comparison to native 64-mT MRI, the deep learning generative model LowGAN offered enhanced white matter lesion conspicuity and image quality in a study involving patients with multiple sclerosis.

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

An emerging nomogram model for intra-tumoral heterogeneity quantification with breast MRI demonstrated an average 85 percent sensitivity in external validation testing for predicting pathologic complete response to neoadjuvant chemotherapy for breast cancer.

Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.